{"filing":{"accession_number":"0001193125-26-277653","cik":"0001404281","ticker":"ELDN","company_name":"Eledon Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"eldn-20260618.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1404281/000119312526277653/eldn-20260618.htm"},"events":[{"id":12858,"run_id":11408,"accession_number":"0001193125-26-277653","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Eledon Pharmaceuticals held its Annual Meeting of Stockholders on June 22, 2026, at which shareholders voted on and approved three proposals: election of Class III Directors (Gros, Hillson, Robinson), approval of an amendment to increase authorized common shares from 300 million to 450 million, and ratification of Deloitte \u0026 Touche LLP as independent auditor.","company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9824,"accession_number":"0001193125-26-277653","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure describes a routine amendment to the Certificate of Incorporation increasing authorized common shares from 300 million to 450 million, approved by stockholders at the Annual Meeting. While governance-related, this is a standard administrative action that does not materially affect the registrant's financial condition, operations, or risk profile—it merely expands the pool of shares available for future issuance without immediate dilutive effect.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T21:33:28.604201+00:00","company_name":"","ticker":null,"filing_date":""},{"id":9825,"accession_number":"0001193125-26-277653","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of an Annual Meeting of Stockholders. The filing presents voting outcomes for three proposals: election of Class III Directors (Gros, Hillson, Robinson), approval of an amendment to increase authorized common shares from 300M to 450M, and ratification of Deloitte \u0026 Touche LLP as independent auditor. The tabulated vote counts and passage of all three matters are material to investors assessing governance and capital structure changes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T21:33:28.604201+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9824,"accession_number":"0001193125-26-277653","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure describes a routine amendment to the Certificate of Incorporation increasing authorized common shares from 300 million to 450 million, approved by stockholders at the Annual Meeting. While governance-related, this is a standard administrative action that does not materially affect the registrant's financial condition, operations, or risk profile—it merely expands the pool of shares available for future issuance without immediate dilutive effect.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T21:33:28.604201+00:00","company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","filing_date":"2026-06-22"},{"id":9825,"accession_number":"0001193125-26-277653","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of an Annual Meeting of Stockholders. The filing presents voting outcomes for three proposals: election of Class III Directors (Gros, Hillson, Robinson), approval of an amendment to increase authorized common shares from 300M to 450M, and ratification of Deloitte \u0026 Touche LLP as independent auditor. The tabulated vote counts and passage of all three matters are material to investors assessing governance and capital structure changes.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T21:33:28.604201+00:00","company_name":"Eledon Pharmaceuticals, Inc.","ticker":"ELDN","filing_date":"2026-06-22"}]}